RFLNA抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P09112(RFLNA Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09112(RFLNA Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The RFLNA (Ret Finger-Like Protein N-Terminal Associated) antibody targets a protein belonging to the RFPL family, characterized by a RING-finger domain critical for E3 ubiquitin ligase activity. These proteins are implicated in ubiquitination pathways, regulating processes like protein degradation, DNA repair, and cell cycle control. RFLNA, specifically, is less studied compared to other family members (e.g., RFPL1-3), but emerging research links it to neurodevelopment and germ cell maturation. It is highly expressed in the brain and testes, suggesting roles in neuronal differentiation or spermatogenesis.

Antibodies against RFLNA are primarily used in research to investigate its expression patterns, interactions, and functional mechanisms. They enable techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding in localization studies within tissues or subcellular compartments. Dysregulation of RFLNA has been tentatively associated with neurological disorders and infertility, though mechanistic insights remain limited.

Commercial RFLNA antibodies are typically raised in rabbits or mice using synthetic peptides or recombinant protein fragments. Validation includes specificity tests (knockout controls) and application-based assays. Challenges include cross-reactivity due to homology within the RFPL family. Ongoing studies aim to clarify RFLNA’s role in ubiquitination networks and disease, positioning it as a potential biomarker or therapeutic target.